Expect a dramatic finale to the Humira patent saga

Saturday Opinion: Alvotech’s speedy infringement trial could see its product jump the queue of adalimumab biosimilars in the final months before AbbVie’s exclusivity comes to an end

Get unlimited access to all IAM content